Funding underscores confidence in Caregility’s AI and computer vision solutions that reduce staff burden and enhance patient care.

WALL, N.J., Sept. 23, 2025 — Caregility Corporation, an enterprise telehealth leader dedicated to connecting care for patients and clinicians everywhere through innovative virtual care and AI-powered solutions today announced it has raised an additional $25.1 million through its Series A-2 Preferred Stock and Series C funding rounds. The round was led by Star Mountain Capital, with participation from a number of sources, including management, Dr. York Wang, PhD, initial founders, and high-net-worth healthcare-focused investors. This financing brings the total outside investment in Caregility to $92 million.

The new capital will accelerate Caregility’s growth initiatives, with a focus on leading in artificial intelligence solutions, computer vision, ambient listening, and sensor-based solutions that improve clinical workflows, reduce staff burden, and enhance patient care.

“Caregility is setting the standard for innovation in hospital-based virtual care, with groundbreaking capabilities such as edge-based Computer Vision AI and audio sensing room duress detection,” said Dr. David Shulkin, M.D., Independent Board Member of Caregility.  “Caregility has expanded these advancements globally, and their platform is uniquely positioned to redefine how hospitals deliver safe, efficient, and high-quality care.”

Caregility has established itself as one of the world’s most widely adopted enterprise telehealth platforms, with more than 30,000 connected devices, over 6 million virtual sessions conducted annually, and deployments across 1,500 hospitals and 75+ health systems. The company’s modular platform supports a comprehensive range of solutions spanning virtual nursing, e-sitting, hospital-at-home, specialty consults, operating room telehealth, and more. Recognized for its reliability and flexibility, Caregility is the only organization in the space serving customers on a truly global scale, with successful deployments in markets including Asia-Pacific, Gulf Region, Middle East, and Canada, in addition to the U.S.

“This strategic investment strengthens our ability to accelerate innovation and scale more aggressively in the marketplace,” said Tod A. Nestor, Chief Financial Officer of Caregility. “With this capital, we can advance AI-driven solutions that meaningfully reduce clinician burden, improve patient outcomes, and deliver measurable and tangible value of the connected care programs deployed by our hospital partners.”

“Caregility is at a pivotal moment in its growth,” said Ron Gaboury, Chief Executive Officer of Caregility. “We’ve built a trusted foundation with many of the world’s leading hospitals and health systems, and this funding empowers us to accelerate the next wave of innovation that will shape the future of smart hospitals and connected care.”

About Caregility

Caregility (www.caregility.com) is a telehealth solutions company dedicated to connecting patients and clinicians everywhere. Our Caregility Connected Care™ platform powers a full suite of clinical and operational applications, enabling care delivery across the continuum, from the hospital to the home. With secure, reliable, and scalable technology, Caregility is transforming healthcare by making virtual care a seamless extension of the care team.

SOURCE Caregility

SALT LAKE CITY, Sept. 23, 2025 — Filevine, the pioneer of the Legal Operating Intelligence System, has raised $400 million in an all-equity financing, underscoring investor confidence in both the legal tech market and Filevine’s growing market share. Over a 15-month period, Filevine closed two funding rounds. The first was led by Insight Partners, followed by a larger subsequent round that brought in Accel and Halo Fund to co-lead alongside Insight Partners, with participation from previous investors including Meritech, Stepstone, Run Ventures, and Album Ventures, reflecting strong momentum and investor conviction. New capital will allow Filevine to scale products that already show meaningful acceleration and expand AI capabilities. Additionally, this capital will fuel go-to-market strategy.

Leading software investors with deep category expertise saw clear product-market momentum, accelerating AI adoption, and a durable business built over the course of the past decade. This cements Filevine as a category-defining legal technology platform built with AI and fully integrated into the operating system legal teams rely on daily. While fragmented tools create silos and provide limited or incorrect insight, Filevine delivers one holistic AI platform giving legal teams the scale, data, and connectivity they need to deliver real business impact. No other legal tech company natively brings together emails, text messages, deadlines, contacts, documents, deposition videos (and transcripts), phone logs, notes, tasks, audit logs, intake notes, and calendars to deliver case-critical and reliable intelligence like Filevine. Filevine’s advantage is context + adoption: AI is embedded in daily legal work and already delivering results. Filevine users upload more than 20 million pages of documents daily, underscoring the platform’s scale and reliability.

The company has grown rapidly since its founding, with nearly 6,000 customers and 100,000 legal professionals using Filevine across boutique firms, government agencies and Fortune 500 enterprises. Filevine’s long history of taking care of customers is evidenced by over 96% gross retention of Filevine Core, its platform and flagship product, and boasts best-in-class customer retention and Net Dollar Retention over 120%.

Filevine will use proceeds from the raise to further its lead in serving litigators, attract top talent, and deepen its base of enterprise and government customers. With its scale, proprietary data, and embedded AI, the company is positioned to define the future of the legal technology market.

“Some early versions of legal AI forced lawyers to work in two systems: their systems of record and their AI tools. But that framework isn’t what the market demands. Filevine embeds intelligence into the DNA of daily legal work, with the first true legal operating intelligence system. Every task a legal professional completes should be augmented with intelligence,” said Ryan Anderson, Founder & CEO of Filevine.

Rebecca Liu-Doyle, Managing Director at Insight Partners added: “Filevine has proven its ability to sustain tremendous growth while simultaneously capturing new opportunities and markets. We at Insight are highly impressed with Ryan and team, and we’re excited to double down with Filevine as they continue scaling into this next chapter.”

John Locke, Partner at Accel shared: “Filevine is tackling a problem that others are missing by developing a system of record where AI is seamlessly woven into every function, and scalable for small firms to enterprise operations. The company’s track record speaks for itself: consistent revenue growth, exceptional client retention, and a product that legal teams desperately need. We’re excited to back Filevine as they lead the legal tech space.”

Ryan Smith, Co-founder of Halo Fund, said: “During diligence, we saw Filevine’s AI products have heavy daily usage, with over 20% week over week growth in their cross-platform AI-chat tool. With about 130% YoY AI revenue growth, users told us they are deriving real value from Filevine’s integrated AI products.”

For more information about Filevine’s Legal Operating Intelligence System that will replace disparate systems and eliminate deficient data sets for legal teams, visit https://filevine.com.

About Filevine
Filevine is headquartered in Salt Lake City, Utah with offices globally. For 10+ years, Filevine has been the legal work platform of record, now it is transforming legal work into legal intelligence. Its Legal Operating Intelligence System bridges the gap between traditional case management and the advanced capabilities modern legal teams demand. Built for success, Filevine empowers elite law firms, global enterprises, and government agencies alike. With AI built-in, not bolted-on, Filevine unifies case management, document automation, communication, billing, compliance, and analytics in one intelligent platform. Recognized as a leader in legal technology, Filevine has been honored by the LegalTech Breakthrough Awards, The SaaS Awards, Deloitte Technology Fast 500, and the Business Intelligence AI Excellence Award (2025). Today, thousands of firms and organizations trust Filevine to deliver speed, strategy, and measurable outcomes across every legal matter.

About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 875 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

About Accel
Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Bumble, CrowdStrike, Fiverr, Flipkart, Freshworks, Qualtrics, Scale, Segment, Slack, Spotify, Squarespace, Tenable, and UiPath are among the companies Accel has backed over the past 40+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com or www.twitter.com/accel.

About Halo Fund
Halo Fund is an investment platform dedicated to fueling the growth of high-potential businesses. The fund helps companies accelerate by providing access to the arenas where attention and adoption scale fastest—the convergence of technology, sports, and entertainment. Founded by Ryan Smith and Ryan Sweeney—drawing on their experience at Qualtrics, Accel, the Utah Jazz, and the Utah Mammoth—the team brings decades of combined expertise as operators and investors in technology. This perspective positions Halo Fund to guide companies through today’s rapidly shifting business landscape. At its core, Halo Fund is built on a simple conviction: the drivers of sustainable growth have changed. Capital and connections alone are no longer enough. Success now depends on harnessing cultural momentum to break through barriers, define markets, and engage directly with the audiences that matter most. By partnering with visionary founders and high-growth companies, Halo Fund helps portfolio businesses capture attention, accelerate adoption, and scale with impact in an increasingly dynamic market environment. For more information, visit hxco.com or follow on X @haloxco.

SOURCE Filevine

NEW YORK, Sept. 23, 2025 — Testkube, the Continuous Testing Platform, today announced an $8 million Series A funding round led by existing investors Ratmir Timashev, co-founder of Veeam Software, and global software investor Insight Partners. The new round underscores a growing recognition that while AI has supercharged the speed of software development, software quality has not kept pace.

Testkube started as an open-source project enabling users to leverage existing on-prem infrastructure and to make running tests less of a headache. Developers and platform engineers quickly adopted the platform for its ability to solve real problems quickly, and since then, Testkube Control Plane and its open-source agent have grown into a full enterprise platform. To date, the company has powered over 100 million automated tests for organizations ranging from fast-growing startups to enterprises like Cloudflare, Siemens, Adobe, and Volvo.

“AI is rewriting the rules of software development, yet it also makes testing significantly harder,” said Dmitry Fonarev, CEO of Testkube. “Traditional testing and CI/CD tools weren’t built for AI-driven or cloud-native scale. Testkube gives developers and platform teams the confidence to ship fast without sacrificing reliability – because untested software is unsafe software.”

Seed investors who backed Testkube’s vision at inception formally participated in this round, reinforcing their early conviction in the company’s approach. Their reinvestment also reflects the pressing need for tooling that ensures reliability as AI reshapes the pace of development. Testkube’s customer base includes financial services, healthcare, tech, government and more, demonstrating the widespread need to automate testing at scale.

With Testkube, companies can synchronize their testing tools and strategies – from API to End-to-End, load, security, and AI-behavior testing – directly into Kubernetes-native workflows. The result is continuous testing at scale, with full visibility and control across teams, environments, microservices, and CI/CD pipelines. Testkube can orchestrate testing tools or frameworks, including Playwright, Cypress, Selenium, k6, and Postman, to name a few, into heterogeneous, scalable, optimized workflows.

“AI doesn’t just change what we build – it changes how we build. Development is becoming more autonomous, code is being generated by machines, and decisions are happening faster than humans can follow,” added Ole Lensmar, Testkube CTO and co-founder. “That makes continuous testing the ultimate safety net. Testkube is the layer that can help ensure every change, human or AI-generated, is tested before it reaches production.”

“Cloud-native development and AI have changed the tempo of software creation,” said Mike Triplett, Managing Director at Insight Partners. “Testkube is addressing the next big bottleneck, helping ensure that testing keeps up with AI’s acceleration.”

Testkube is also actively integrating AI into its capabilities like intelligent test orchestration (deciding on which tests to run when), automated remediation (suggesting fixes for failed tests), and adaptive performance testing (adjusting load configurations based on desired and actual outcomes), which help teams ship faster and more confidently. “AI is great at creating velocity, but without scalable quality, it’s a false sense of progress,” said Timashev. “Testkube ensures the gains from AI don’t come at the cost of reliability.”

Founded in 2023 as a spin-off from Kubeshop, Testkube is focused on solving challenges teams face when scaling software test automation – by giving teams speed, flexibility, and control without forcing them to abandon their existing tools.

SOURCE Testkube

Deal Reinforces HighVista’s Expanding Secondary Market Capabilities

BOSTON, Sept. 23, 2025 — HighVista Strategies LLC (“HighVista” or the “Firm”), an employee-owned specialty alternative asset manager, has closed a bespoke secondary transaction to provide liquidity for investors in mature venture capital funds. This deal, involving seven HighVista funds with over $425 million in net asset value, utilized various structures, including traditional sales and hybrid continuation vehicles, which helped to provide investors added flexibility to sell or retain their interests. The process, managed with Evercore, attracted over 40 potential bidders, reflecting HighVista’s strategic approach in today’s evolving market where companies are remaining private for longer.

Kirsten Morin, Co-Head of Venture Capital at HighVista, highlighted the Firm’s focus on active portfolio management, stating, “We’re proud to deliver an innovative liquidity solution that accelerates realized returns for our investors, showcasing our team’s ability to navigate complex market dynamics. We appreciate the continued trust our investors place in us and remain laser focused on delivering value through every market cycle.”

Building on a recent lower middle market buyout transaction that proactively accelerated liquidity for clients, this venture transaction extends HighVista’s engagement in the secondary market, where the Firm has long utilized secondaries both to generate liquidity and to identify differentiated opportunities across strategies.

“The secondary market has become a central part of private markets, and HighVista is well-positioned to capitalize on it from both sides,” said Raphael Schorr, Deputy Chief Investment Officer at HighVista Strategies. “It’s a powerful tool for generating liquidity in a market where traditional exits have slowed, and it offers potential for attractive, risk-adjusted returns. Our integrated platform gives us a distinct analytical edge, enabling us to structure sophisticated solutions for our own funds and act as a strategic capital partner for transactions sourced through our network.” 

About HighVista
HighVista Strategies LLC is an employee-owned alternative asset manager that brings investors alpha opportunities in structurally inefficient markets. Based in Boston and founded in 2004, HighVista manages $10.5 billion of capital on behalf of sophisticated investors globally. Our culture combines inquisitive thinking with rigorous discipline, enabling us to identify and execute on opportunities with high conviction. HighVista is a partner for investors looking beyond the standard playbook for differentiated ideas that can amplify returns. HighVista’s investment strategies span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-strategy alternatives.

Media Contact
Prosek Partners for HighVista
[email protected]

Important Disclosure

The views and options expressed here reflect the judgments and opinions of HighVista Strategies LLC at the time of this publication, do not purport to be complete, and are subject to change. No obligation to update or otherwise revise such views and opinions is being assumed. This publication does not constitute, and should not be construed as, an offer of advisory services, securities or other financial instruments, a solicitation of an offer to buy any security or other financial instrument, or a recommendation to buy, hold or sell a security or other financial instruments in any jurisdiction.  Information provided herein is based upon data and analysis that is believed to be accurate as of the time of writing, but no representation or warranty is made herein. THIS PUBLICATION CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE U.S. FEDERAL SECURITIES LAWS.  FORWARD-LOOKING STATEMENTS ARE THOSE THAT PREDICT OR DESCRIBE FUTURE EVENTS OR TRENDS AND THAT DO NOT RELATE SOLELY TO HISTORICAL MATTERS.  FOR EXAMPLE, FORWARD-LOOKING STATEMENTS MAY PREDICT FUTURE ECONOMIC PERFORMANCE, DESCRIBE PLANS AND OBJECTIVES OF MANAGEMENT FOR FUTURE OPERATIONS, PERFORMANCE AND RISK AND MAKE PROJECTIONS OF REVENUE, INVESTMENT RETURNS, RISK CALCULATIONS OR OTHER FINANCIAL ITEMS.  FORWARD-LOOKING STATEMENTS CAN GENERALLY BE IDENTIFIED AS STATEMENTS CONTAINING THE WORDS “WILL,” “BELIEVE,” “EXPECT,” “ANTICIPATE,” “INTEND,” “CONTEMPLATE,” “ESTIMATE,” “ASSUME,” “TARGET” OR OTHER SIMILAR EXPRESSIONS.  SUCH FORWARD-LOOKING STATEMENTS ARE INHERENTLY UNCERTAIN, BECAUSE THE MATTERS THEY DESCRIBE ARE SUBJECT TO KNOWN (AND UNKNOWN) RISKS, UNCERTAINTIES AND OTHER UNPREDICTABLE FACTORS, MANY OF WHICH ARE BEYOND CONTROL.  NO REPRESENTATIONS OR WARRANTIES ARE MADE AS TO THE ACCURACY OF SUCH FORWARD-LOOKING STATEMENTS. 

SOURCE HighVista Strategies LLC

Investment accelerates the development of the open-source Obot MCP Gateway and Nanobot MCP Agent Framework

SAN FRANCISCO, Sept. 23, 2025 — Obot AI, an open-source software company building secure, enterprise-ready platforms for the emerging Model Context Protocol (MCP) standard, today announced a $35 million seed funding round.

The round was co-led by Mayfield Fund and Nexus Venture Partners.

The new capital will support Obot as it expands the development of its open-source projects, including the Obot MCP Gateway and Nanobot MCP Agent Framework, and grows its engineering and product teams. Launched in August 2025, the Obot MCP Gateway offers a unified, open-source control plane that enables IT teams to manage and secure MCP servers and build MCP-enabled AI solutions.

“The MCP standard is reshaping how organizations adopt AI,” said Sheng Liang, CEO of Obot AI. “But without a standard platform, companies struggle with fragmentation, governance, and integration challenges. Obot AI is building an Enterprise MCP Platform so every organization can safely adopt, scale, and innovate with AI assistants.”

As more enterprises integrate AI tools and capabilities, IT leaders are grappling with the challenge of providing access while maintaining control and ensuring safety. The Obot MCP Gateway addresses this gap by giving organizations a clear path to adopt new technology. Nanobot introduces a full agent framework built around MCP and MCP-UI, paving the way for rich AI agents capable of delivering a dynamic UI directly within the chat interface.

“Enterprises urgently need a way to unlock the value of AI assistants while ensuring governance, security, and trust,” said Ursheet Parikh, Partner at Mayfield Fund. “Obot AIs MCP Platform is the missing piece of enterprise infrastructure, and we’re thrilled to support Sheng and his team as they bring this vision to life.”

“The Obot team has a proven track record of building critical open-source infrastructure platforms for developers and enterprises,” said Jishnu Bhattacharjee, Managing Director at Nexus Venture Partners. “We believe Obot AI will become the standard foundation for how enterprises integrate AI tools and agents.”

Obot’s founding team previously created Rancher Labs (acquired by SUSE) and Cloud.com (acquired by Citrix), two companies that redefined how enterprises adopt open-source platforms at scale. With Obot.ai, the team focuses on doing the same for AI technologies.

To learn more about Obot or the recent Obot MCP Gateway and Nanobot projects launch, visit https://obot.ai.

About Obot.ai
Obot AI is building an open-source Enterprise MCP Gateway to accelerate the adoption of AI technology in the Enterprise. By providing a standard, open-source foundation for building, running, and scaling MCP servers, Obot AI enables enterprises to move from experimentation to real-world adoption with governance, security, and trust. Obot AI was founded by the team behind Rancher Labs (acquired by SUSE) and Cloud.com (acquired by Citrix). For more information, visit Obot.ai or explore our projects on GitHub.

Media Contacts

Taylor Sullivan           
PANBlast
[email protected]

Connie Lin
Obot AI
[email protected]

SOURCE Obot.ai

The oversubscribed round, led by Wellington Management and General Catalyst, will be used to enhance and scale the Company’s Enterprise Health Platform, and transform health benefit management and administration for employers and plans

Rebrand signals the Company’s evolution as a full-spectrum benefits technology partner for employers and health plans, including its next-generation pharmacy benefit manager (PBM)

NEW YORK, Sept. 23, 2025 — Capital Rx, Inc., the enterprise health technology company and benefit administrator, today announced a $400 million investment, including a $252 million Series F funding round along with additional investments into the Company’s securities, scheduled to close in early October, led by Wellington Management and General Catalyst, with participation from Generation Investment Management, Growth Equity at Goldman Sachs Alternatives, 9Yards Capital, B Capital, Edison Partners, Prime Health Investments, and Transformation Capital, among others. Concurrent with the investment, the Company is rebranding as Judi Health™ to better reflect its roots and broadened capabilities as a full-service health benefits technology company helping employers design and manage health benefit programs that meet their unique needs.

The transition to Judi Health and supportive funding marks a pivotal moment in addressing the fundamental inefficiencies of health benefits administration and the rising cost of care in the U.S., which is projected to jump almost 9% in 2026, marking the sharpest increase in over a decade. Despite this drastic increase in cost, Americans’ health outcomes are getting worse. Patients struggle to understand the true cost of their healthcare visits, prescriptions, and procedures, and this lack of transparency often results in delayed or deferred care for what could be a life-saving treatment. 

“Judi Health is rewriting the playbook for how benefits are delivered,” said Joshua Sommerfeld, Healthcare Sector Lead at Wellington Management. “By combining a transparent PBM model with a scalable, AI-powered platform, they’re building the infrastructure for the next generation of health benefit administration. Employers are demanding better solutions, and Judi Health is uniquely positioned to meet that moment.”

The oversubscribed financing round will help the company expand its PBM operations and fuel the deployment of Judi Health’s Enterprise Health Platform (EHP) to bring a full suite of employer-facing health benefits services that meet evolving customer needs with clarity and flexibility through brands including:

• Capital Rx, which will continue to operate as an industry-leading, transparent PBM, recognized for its flat-fee-based, aligned pricing model, member-centric service approach, and operational efficiency.
• Judi Health™, the company’s full-service health benefit management platform that integrates unified care navigation through Judi Care™ for pharmacy, medical, vision, and dental benefits with unified claim administration and related workflows, allowing employers and plan members to easily manage all their health benefits through a single solution.
• Judi^®, short for adjudication, is the company’s purpose-built EHP. Judi^® provides administrative workflows for millions of plan members across Fortune 500 companies, the largest unions in America, leading health systems, Medicare and Medicaid plans, and top academic institutions.

“With Judi, Capital Rx has built a platform that not only meets the needs of today’s employers and health plans, but is engineered to adapt and grow with them,” said Holly Maloney, Managing Director at General Catalyst. “We believe their leadership in transparent PBM and their vision to unify pharmacy and medical benefits represent a transformative shift in healthcare administration, and we look forward to deepening our relationship.”

Founded in late 2017 by Chief Executive Officer AJ Loiacono and Chief Technology Officer Ryan Kelly, Judi Health has earned national recognition for its technology advancements and aligned pricing model in pharmacy benefit management, a foundation it will maintain and build upon. With more than 4 million employer PBM members and over 54 million health plan lives already contracted to run on the Judi platform, developed from the ground up, the company is entering the broader health benefits market as an innovator and leader with deep experience, proven infrastructure, and a robust customer base.

“We believe that Judi Health is building the foundational infrastructure for a more transparent U.S. healthcare system,” said Jonah Surkes, Director at Generation Investment Management. “For as long as health benefits remain obscured by misaligned incentives and legacy technology, patients will continue to suffer, whether at pharmacy counters or hospital beds. Today, as Judi Health expands from pharmacy into unified claims and full benefit administration, we see it reaching a critical inflection point — and we are pleased to partner with them at this moment of acceleration.”

“We’ve seen unprecedented demand for Capital Rx, our transparent pharmacy benefit offering, and with the introduction of Judi Health, we are able to help our customers also administrate medical, dental, and vision benefits on a single platform,” said Loiacono. “The U.S. healthcare ecosystem has far too many ‘rent seekers’ inflating costs, hiding fees, and delivering substandard care due to a combination of misalignment and a reliance on antiquated technology. Judi Health is not just the promise of better care; it is the technology that powers the future of U.S. healthcare.”

About Judi Health
Judi Health is a health technology company providing a comprehensive suite of solutions for employers and health plans, including:

• Capital Rx: a public benefit corporation delivering full-service pharmacy benefit management (PBM) solutions to self-insured employers
• Judi Health™: full-service health benefit management for employers, TPAs, and health plans
• Judi^®: a single, scalable SaaS solution that health plans can utilize to manage all their claim workflows

Through these solutions, Judi Health is executing on its mission to give our country the infrastructure it needs for the healthcare we deserve. To learn more, visit www.judi.health.

Media Contacts
Michael Passanante, SVP, Marketing & Communications
Justin Venneri, Senior Director, Communications
[email protected] 

‍Alex Jenkins, 120/80 MKTG
[email protected]

SOURCE Capital Rx

WAGENINGEN, Netherlands and DINTELOORD, Netherlands, Sept. 23, 2025 — Dutch food-tech scale-up Revyve has raised nearly €24 million in Series B financing, bringing its total capital raised to more than €40 million. The investment will accelerate the company’s commercial rollout of functional yeast proteins designed to replace eggs and additives in mainstream food categories.

The Series B round was co-led by ABN AMRO Sustainable Impact Fund and Invest-NL with regional support from Brabantse Ontwikkelings Maatschappij (BOM) and strategic investments by Lallemand Bio-Ingredients’ Swiss affiliate Danstar Ferment and Grey Silo Ventures (CVC of Cereal Docks Group). Existing investors Oost NL and Royal Cosun doubled down on their commitment. This diverse investor base combines institutional, public, and strategic expertise to back Revyve’s mission of reshaping and transforming the alternative protein space by powering next-gen clean-label solution.

Clean-label solutions for a changing food landscape

Revyve produces highly functional yeast proteins that mimic the performance of eggs in food categories such as bakery, sauces, alternative meat and plant-based dairy. Unlike many substitutes, Revyve’s ingredients are natural, more sustainable, and price competitive, helping manufacturers respond to three pressing industry challenges:

• Rising egg costs: Volatile pricing is driving demand for affordable and price stable alternatives.
• Scrutiny of ultra-processed foods: Brands are under pressure to eliminate additives while keeping functionality.
• Sustainability: Major retailers and food manufacturers are demanding cuts to CO₂ footprints across the supply chain.

“Food manufacturers are cutting back on eggs to offset increasing prices and reach sustainability targets, but replicating their unique functionality is crucial to maintaining the texture and mouthfeel consumers are used to. This is exactly where our Yeast Proteins come in, providing an affordable and clean label solution for egg replacement or egg reduction” said Cedric Verstraeten, CEO of Revyve. “This funding round marks a tipping point for us: allowing us to modularly scale production and branch out to more food categories and serve our sustainable solutions to larger customers worldwide”

Scaling production in the Netherlands

In 2024, Revyve commissioned its first-of-a-kind (FOAK) production facility in Dinteloord, the Netherlands. Already running at capacity for several customers, the site has proven the company’s ability to produce and sell industrial volumes. With this new investment, Revyve will expand output to over 1,600 tons per year, ensuring reliable supply for global accounts.

Verstraeten adds: “Strong regional support from both the Wageningen and Brabant ecosystems has enabled us to scale to industrial levels in record time.  With a stellar team and strong investor backing, we have an incredibly solid foundation for global expansion.”

Strong investor backing

The Series B round marks strong confidence in Revyve’s proprietary technology and market potential.

• “We are excited to partner with Revyve as they pioneer pressing sustainable alternatives to traditional egg ingredients. Their solution addresses a critical need in the food transition: scalable ingredients with a low environmental footprint and compelling economics for food manufacturers. We believe this combination of commercial viability and measurable sustainable benefits makes Revyve uniquely positioned to grow into a global leader. We look forward to supporting their journey.” said Hanna Zwietering, ABN AMRO SIF Senior Investment Manager.
• Lisette Kersting-van der Boog, Senior Investment Manager of Invest-NL adds: “With their functional egg-replacement ingredients, Revyve can play a major role in accelerating the global protein transition and fostering circular solutions that reduce pressure on land, water and animals. We are proud to invest in this Dutch company, which strengthens the country’s innovative power with a pioneering technology that has the potential to transform food production worldwide.”
• Furthermore, the plans of Revyve fit perfectly in the BOM’s ambition to grow Brabant into ‘the Scale-Up Plant of Europe‘: “Revyve’s plans align seamlessly with our mission to position Brabant as the Scale-Up Plant of Europe. Their breakthrough technology not only contributes to a more sustainable food system but also exemplifies the kind of bold innovation we aim to foster in the region. We’re proud to support Revyve in scaling their impact from Brabant to the world,” added Ingrid Nieweg, Investment Manager at BOM.”
• Lallemand Bio-Ingredients and Grey Silo Ventures (CVC of Cereal Docks Group) complete Revyve’s Series B round, bringing a wealth of knowledge and synergies in yeast innovation and agri-food expertise.

Looking ahead

With industrial production in full swing, Revyve is already serving customers across Europe, UK, USA, Canada, Mexico and Australia. Building on this momentum, the company will showcase its latest applications and partnerships this autumn at two major industry tradeshows: Anuga (4-8 October, Cologne, Hall 01.2 | Stand D028g-E029g) and Food ingredients Europe (2-4 December, Paris, Stand #73J23).

About Revyve

Revyve, is a purpose-driven food-tech company committed to creating a more sustainable food system. The team of scientists and food industry experts at Revyve share a common vision of enhancing the sensory experience of food through incredible texture. The company arose from Wageningen University & Research (WUR) in the Netherlands, where its founding scientists discovered the potential of yeast to mimic the functionality of eggs. Revyve’s ingredients introduce authentic textures that help replace animal proteins and “clean up” product labels.
www.revyve.bio

About ABN AMRO Sustainable Impact Fund

The ABN AMRO Sustainable Impact Fund is one of the largest private impact funds in the Netherlands and invests in companies that have a positive impact on climate. With a commitment of EUR 500m, funded and managed exclusively by ABN AMRO, we invest through direct equity investments in key transition sectors and focus on the energy transition, the built environment and sustainable consumption.

ABN AMRO Sustainable Impact Fund – ABN AMRO  

About Invest-NL

Invest-NL is the National Promotional Institution of the Netherlands, committed to driving a sustainable and innovative future. We accelerate and finance major societal transitions in the fields of Agrifood, Biobased & Circular Economy, Deep Tech, Energy, and Life Sciences & Health. We remove barriers, mobilise capital, and help develop emerging sectors. Through capital, expertise, and new financial instruments, we invest in tomorrow’s solutions.

www.invest-nl.nl

About Brabantse Ontwikkelingsmaatschappij (BOM)

The Brabant Development Agency (BOM) works together with entrepreneurs to create a future-proof Brabant economy. We share knowledge, develop networks, and provide capital to innovative Brabant companies and sustainable energy projects. We also encourage forward-looking international companies to settle in Brabant and assist companies already based in Brabant to extend their reach abroad. 

http://www.bom.nl

About Grey Silo Ventures

Grey Silo Ventures is the Corporate Venture Capital arm of Cereal Docks Group, dedicated to investing in non-animal-based ingredients and breakthrough technologies in food-tech and ag-tech. With deep roots in plant-based processing, Grey Silo Ventures supports innovation in fermentation, green proteins, cellular agriculture, and functional ingredients.

www.greysiloventures.com

About Lallemand Bio Ingredients

Lallemand Bio-Ingredients is business unit of Lallemand Inc which is a privately-owned business, headquartered in Canada, with over 6,000 employees across 50 countries and 58 production sites worldwide. Lallemand is a global leader in microbial solutions, combining deep scientific expertise with a century-long commitment to innovation and sustainability. Lallemand Bio Ingredients researches, develops, produces and markets food ingredients and flavours made from yeast fermentations at ten production plants located across North America and Europe which produce ingredients including inactive yeast, yeast extracts & autolysates that support the sustainability and natural/clean label status of food products.

http://www.bio-lallemand.com/

For press inquiries, please contact:

Photo – https://mma.prnewswire.com/media/2778025/Revyve_Funding.jpg

SOURCE Revyve

The new automaker proves market differentiation and capital-efficient business model with strategic backing from top investors

SAN CARLOS, Calif., Sept. 23, 2025 — TELO Trucks, maker of the first electric mini truck built for U.S. cities, today announced its oversubscribed $20M Series A funding. This funding round was led by legendary designer Yves Behar, and Marc Tarpenning co-founder of Tesla and Venture Partner of Spero Ventures. Additional investment came from TO VC, E12 Ventures, Neo, Marc Benioff, Uncorrelated Ventures, Nova Threshold, MCJ, and others.

TELO Trucks stands out in the market with a new category of trucks that meets a critical need for functionality across both consumer and fleet audiences. The TELO MT1 delivers the capabilities of a full-size crew cab work truck in the footprint of a 2-door MINI Cooper.

Yves Behar, co-founder of TELO Trucks said: 
“I have great confidence in the TELO team as we build a future-proof vision for mobility. The MT1 proves that innovation can deliver smarter design, greater practicality, and uncompromised capability, shaping how we’ll all move tomorrow.”

Marc Tarpenning, Venture Partner at Spero Ventures said: 
“TELO has the vision, product, capital efficiency, and manufacturing strategy to make the next great transportation company.”

This round follows TELO’s $6M strategic Seed round, led by Neo, and their previous $2M Pre-Seed, led by GoAhead Ventures.

Capital Efficiency

TELO has demonstrated a first-of-its-kind effort in capital efficiency. With only $8M raised over the past three years, TELO launched two fully realized pre-production prototypes that have already earned critical acclaim from the automotive media. This overtakes other automakers who have required in excess of $50M to achieve the same milestone, making TELO the most capital efficient automaker ever.

Joshua Phitoussi, Managing Partner at TO VC said:
“Disciplined scale-up is the name of the game in auto manufacturing. Many companies have made the fatal mistake of scaling up too fast, with too few proof points of product-market fit. TELO, on the other hand, has a liquid and well understood bill-of-materials, and CAPEX-light manufacturing model that leans on blue-chip partners, and 12,000 reservations that get the company well past profitability. This team has shown that they can execute with scarce resources. We’re excited to see what they can do now with strong funding and long-term partners.”

With this new tranche of capital, TELO intends to reach production readiness and pass all federal requirements to get the TELO MT1 on the road.

Strong Market Demand

With over 12,000 pre-orders, representing $600M+, TELO has struck a chord with American consumers. TELO builds right-sized trucks that buck the trend for super-sized, impractical and inefficient alternatives currently available on the market. At just 152 inches in length, the MT1 has the same truck bed length as the Toyota Tacoma and the capability of towing 6,600lb.

Uncompromising Utility

The TELO MT1 all-electric mini truck is over 5 feet shorter than the most popular mid-sized trucks, and two-feet shorter than the 1980s “small trucks” of the past. The world’s most efficient EV pickup, the TELO MT1, delivers:

• Seating for 5 adults
• A 5-foot bed that extends to 8 feet with a folding mid-partition
• Once extended, the bed has space to fit plywood flat on the floor (not over wheel wells)
• All-wheel drive
• Up to 350 miles of range
• Exceptional navigability for high-density towns and cities

Compact in size, the TELO MT1 sets a new standard for what a truck can be.

For more information about TELO, or to pre-order a TELO Truck for only $152 — the length in inches of the vehicle — please visit www.telotrucks.com.

About TELO Trucks
Co-founded by CEO Jason Marks,  CTO Forrest North, and CCO Yves Béhar, with design contributions from fuseproject, TELO Trucks is shrinking the mobility footprint. Its signature TELO Truck, launched in June 2023, combines the bed capacity of a standard pickup and the comfort of a crew cabin in a dramatically compact 152-inch vehicle. With over 12,000 pre-orders since launch, TELO represents a new era of capital-efficient EV companies.

Media Contact
Hannah Dudley
TELO Trucks Communications
[email protected]

Press Kit – TELO Trucks
TELO Trucks LinkedIn
TELO Trucks YouTube Channel

SOURCE Telo Trucks

Landmark investment will accelerate access to cannabis-based healthcare as the UK market approaches a £1bn valuation, positioning Mamedica to support up to 100,000 patients.

NEW YORK, Sept. 23, 2025 — Mamedica, the UK’s leading and most-trusted provider of cannabis-based prescription medicines, today announced a £4.5 million funding round led by Casa Verde, the US-based cannabis-focused venture capital firm.

Casa Verde has backed major cannabis companies including Dutchie, Metrc and Leaflink in the United States, and holds European positions in Cansativa and Sanity Group. The new capital will be used to scale Mamedica’s operations by optimising its in-house supply chain for efficiency and continuity of care, expanding access through a wider clinical network, advancing its proprietary digital healthcare platform with enhanced automation and compliance capabilities, and driving education around the integration of medical cannabis into mainstream healthcare.

Launched in 2022 by CEO and founder Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier. Since inception, Mamedica has treated over 10,000 patients, with approximately 7,500 actively under care and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the UK medical cannabis industry approaches £1bn in annual sales by the end of 2028.

“We’re excited to partner with Mamedica as the UK cannabis market enters a period of rapid growth,” said Karan Wadhera, Managing Partner at Casa Verde. “Mamedica’s digital-first, patient-centric model sets the standard for care in the UK and offers a blueprint for broader European expansion.”

“This funding marks a pivotal milestone in Mamedica’s mission to transform patient care in the UK,” said Jon Robson, CEO and founder of Mamedica. “The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment.”

About Mamedica

Mamedica is a digital healthcare platform providing UK patients with access to cannabis-based prescription medicines across pain, psychiatry, neurology, palliative care and cancer. Following a secure video consultation, medication is dispensed and delivered nationwide via next-day courier. Founded in 2022, Mamedica prioritises patient care, safety and satisfaction through proprietary technology, specialist clinicians, experienced pharmacists and dedicated support staff.

SOURCE Mamedica